News

Under the study, Amgen and Allergan evaluated the efficacy and safety of ABP 215 compared with Genentech’s Avastin (bevacizumab) in patients with advanced non-small cell lung cancer. The

The company started enrolling patients in IFN-K-002 double-blind, randomized, placebo-controlled, multi-center study to identify the biological and clinical efficacy of IFNa-Kinoid in patients suffering from SLE. Neovacs intends

Edoxaban is an oral, once-daily, direct factor Xa inhibitor, which is one of the key parts responsible for blood clotting. Under the ENGAGE AF-TIMI 48 global phase 3

Pfizer secured a license for the contraceptive, allowing women to inject themselves at home rather than going to clinic or GP surgery. Sayana Press combines a long-acting, reversible,

CVS/pharmacy has expanded the availability of the opioid overdose reversal medicine, naloxone, in several states. The medication was already available at CVS/pharmacy without a prescription in Rhode Island

The joint research and development effort would leverage Purdue Pharma’s intellectual property and lead compounds, combined with AnaBios’ Phase-X technology. Purdue Pharma has more than 10 years of

The state-of-the-art facility provides the translational bridge between pre-clinical development and phase II clinical trials with end-to-end capabilities, including process development, cell banking, cGMP manufacturing, purification and formulation,

The companies initially focused efforts on lung diseases and will now also include kidney diseases. As part of the agreement, SGI will receive royalties and milestones from the

In the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies, 1,035 patients with genotype 1-6 HCV infection received 12 weeks of SOF/VEL. Among these patients, 21 percent had compensated cirrhosis and